Everspin Technologies, Inc. (MRAM) Forms $7.41 Double Bottom; New Leaf Venture Partners Has Raised Marinus Pharmaceuticals (MRNS) Stake By $1.40 Million

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Logo

New Leaf Venture Partners Llc increased Marinus Pharmaceuticals Inc (MRNS) stake by 70% reported in 2017Q4 SEC filing. New Leaf Venture Partners Llc acquired 175,000 shares as Marinus Pharmaceuticals Inc (MRNS)’s stock declined 54.45%. The New Leaf Venture Partners Llc holds 425,000 shares with $3.47M value, up from 250,000 last quarter. Marinus Pharmaceuticals Inc now has $156.01 million valuation. The stock increased 1.32% or $0.05 during the last trading session, reaching $3.85. About 605,009 shares traded. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has risen 130.72% since April 4, 2017 and is uptrending. It has outperformed by 119.17% the S&P500.

Everspin Technologies, Inc. (MRAM) formed double bottom with $7.04 target or 5.00% below today’s $7.41 share price. Everspin Technologies, Inc. (MRAM) has $123.27 million valuation. The stock increased 3.78% or $0.27 during the last trading session, reaching $7.41. About 59,427 shares traded. Everspin Technologies, Inc. (NASDAQ:MRAM) has declined 3.14% since April 4, 2017 and is downtrending. It has underperformed by 14.69% the S&P500.

Among 3 analysts covering Everspin Technologies Inc (NASDAQ:MRAM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Everspin Technologies Inc had 7 analyst reports since June 5, 2017 according to SRatingsIntel. Needham maintained Everspin Technologies, Inc. (NASDAQ:MRAM) rating on Monday, August 28. Needham has “Buy” rating and $24.0 target. The firm has “Buy” rating by Canaccord Genuity given on Monday, August 14. On Monday, June 12 the stock rating was maintained by Needham with “Buy”. The company was maintained on Friday, August 11 by Needham. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, August 10. The stock of Everspin Technologies, Inc. (NASDAQ:MRAM) earned “Buy” rating by Canaccord Genuity on Thursday, August 24. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, June 5 report.

Investors sentiment decreased to 2 in 2017 Q4. Its down 0.80, from 2.8 in 2017Q3. It worsened, as 7 investors sold MRNS shares while 11 reduced holdings. 23 funds opened positions while 13 raised stakes. 20.53 million shares or 8.19% more from 18.97 million shares in 2017Q3 were reported. Wells Fargo Co Mn holds 27,523 shares. Quantbot Techs Limited Partnership accumulated 8,177 shares or 0.01% of the stock. 416,215 were reported by Deutsche Savings Bank Ag. Arrowmark Colorado Hldgs Ltd Company stated it has 0% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Gsa Capital Llp holds 0.01% or 20,500 shares in its portfolio. Caxton holds 0.18% or 18,643 shares. Susquehanna Intl Group Inc Llp has invested 0% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Citigroup holds 0% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) for 1,277 shares. 1.02M were reported by Citadel Advisors Ltd. Commercial Bank Of America Corp De reported 7,312 shares or 0% of all its holdings. Cormorant Asset Mgmt holds 500,000 shares. New Leaf Venture Limited Liability holds 425,000 shares or 1.62% of its portfolio. Ascend Capital Limited, California-based fund reported 1.01M shares. Balyasny Asset Mgmt Limited Co holds 1.00 million shares. Artal Group Sa holds 0.02% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) for 200,000 shares.

Since December 15, 2017, it had 0 insider buys, and 2 sales for $10.05 million activity. $23,730 worth of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was sold by Smith Edward F. On Friday, December 15 Bain Capital Life Sciences Investors – LLC sold $10.02 million worth of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) or 1.27 million shares.

Among 5 analysts covering Marinus Pharmaceuticals (NASDAQ:MRNS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Marinus Pharmaceuticals had 10 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was downgraded by RBC Capital Markets to “Sector Perform” on Tuesday, June 14. The firm earned “Buy” rating on Wednesday, August 10 by Jefferies. The rating was downgraded by Oppenheimer to “Perform” on Tuesday, June 14. The firm earned “Outperform” rating on Thursday, December 17 by RBC Capital Markets. The firm has “Buy” rating given on Tuesday, March 8 by Stifel Nicolaus. On Monday, March 19 the stock rating was initiated by Mizuho with “Buy”. Jefferies maintained it with “Buy” rating and $2.50 target in Tuesday, June 14 report. The stock has “Outperform” rating by Oppenheimer on Friday, October 30. On Tuesday, November 17 the stock rating was initiated by Jefferies with “Buy”. Oppenheimer maintained it with “Outperform” rating and $21 target in Wednesday, August 5 report.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Institutional Positions Chart